Active substanceImatinibImatinib
Similar drugsTo uncover
  • Genfatinib
    pills inwards 
  • Histamel
    capsules inwards 
    VEROPHARM SA     Russia
  • Gleihib®
    pills inwards 
  • Glivec®
    capsules inwards 
    Novartis Pharma AG     Switzerland
  • Iglib®
    capsules inwards 
  • Imagliv®
    pills inwards 
    Sandoz d.     Slovenia
  • Imatib
    capsules inwards 
  • Imatinib
    pills inwards 
    BIOCAD, CJSC     Russia
  • Imatinib
    pills inwards 
  • Imatinib
    capsules inwards 
  • Imatinib
    pills inwards 
  • Imatinib
    pills inwards 
    JODAS EKSPOIM, LLC     Russia
  • Imatinib Medak
    capsules inwards 
    medac GmbH     Germany
  • Imatinib Forsyte
    capsules inwards 
    Forsythe ZAO     Russia
  • Imatinib-Aktavis
    capsules inwards 
  • Imatinib-Alvogen
    pills inwards 
    Alvogen IPKo S.A.L.     Luxembourg
  • Imatinib-Segardis
    capsules inwards 
    SIGARDIS ENG, LLC     Russia
  • Imatinib-Teva
    capsules inwards 
  • Imatinib-TL
    capsules inwards 
  • Imvek
    capsules inwards 
  • Neopax
    capsules inwards 
    KRKA-RUS, LLC     Russia
  • Filachromin®
    capsules inwards 
    NATIVA, LLC     Russia
  • Dosage form: & nbspcapsules
    Composition:

    1 capsule contains:

    active substance: Imatinib - 100.00 mg (in the form of imatinib mesylate - 119,50 mg):

    Excipients: cellulose microcrystalline - 79.72 mg, copovidone - 22.44 mg, crospovidone - 26.92 mg, sodium stearyl fumarate - 3.92 mg, silicon dioxide colloid hydrophobic - 0.75 mg, silicon dioxide colloidal anhydrous - 0.75 mg.

    Capsule shell: (E 172) - 0.4747 mg, iron oxide red (E 172) 0.0486 mg, black ink (shellac, propylene glycol, lactose, ammonia concentrated, potassium hydroxide, ferric oxide black oxide (E 172)).

    Description:

    Hard capsules №1 of light orange color with the marking "100 mg" black ink on the case.

    Contents of capsules *: light yellow powder.

    Pharmacotherapeutic group:Antitumor agent protein tyrosine kinase inhibitor
    ATX: & nbsp

    L.01.X.E.01   Imatinib

    Pharmacodynamics:

    Imatinib has a selective inhibitory effect on the enzyme Bcr-Abl- tyrosine kinase, formed at the fusion of a gene site Bcr (breakpoint cluster region) and protooncogene Abl (Abelson), at the cellular level, selectively inhibits proliferation and induces apoptosis of the cell lines expressing Bcr-Abl-tyrosine kinase, including immature leukemia cells, formed in patients with positive on the Philadelphia chromosome (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).

    Imatinib selectively inhibits Vsr-Abl-positive colonies obtained from the blood cells of patients with CML.

    Imatinib inhibits proliferation and induces apoptosis of gastrointestinal tract (GI) stromal tumors expressing tyrosine kinase with a c-K mutationit receptor.

    Activation of reviewers to factors of platelet growth or Abl-fragment of tyrosine kinase can cause the development of both myelodysplastic / myeloproliferative diseases, as well as hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (HEL), and swelling dermatofibrosarcoma. Activation c-Kit a reviewer of tyrosine kinase and receptors for platelet growth factors may underlie the pathogenesis of systemic mastocytosis (CM). Imatinib inhibits signal transmission in cells and cell proliferation resulting from a disruption in the regulation of platelet-derived growth factors and stem cells, c-TOit-receptor and AN-fragment tyrosine kinase.

    Pharmacokinetics:

    The pharmacokinetic parameters of imatinib were evaluated in the dose range from 25 mg to 1000 mg. Pharmacokinetic profiles were analyzed on the 1 st day of application, as well as on reaching equilibrium concentrations (Css) Imatinib in the blood plasma on the 7th or 28th day.

    Suction

    After oral administration, the mean absolute imatinib bioavailability is 98%. The value of the coefficient of variation for the area values ​​under the pharmacokinetic curve "concentration-time" (AUC) It is large and amounts to 40-60%. In the range of doses from 25 mg to 1000 mg, a direct linear dependence of the value AUC of the dose value.

    When imatinib is taken with food with a high fat content, in comparison with fasting, there is a slight decrease in the degree of absorption (a decrease in the maximum concentration of imatinib in the blood plasma (Cmax) by 11%, AUC - by 7.4%) and slowing the suction speed (increasing the time to reach Cmax imatinib on 1.5 h).

    Distribution

    According to research in vitro the binding of imatinib to blood plasma proteins when administered at clinically significant concentrations is about 95% (mainly with albumin and acid alpha-glycoproteins, to a small extent - with lipoproteins).

    Metabolism

    Imatinib is metabolized. mainly in the liver with the formation of the main metabolite (N-detylated piperazine derivative) circulating in the systemic circulation. In vitro the imatinib metabolite has pharmacological activity similar to the activity of the starting material. Value AUC metabolite is 16% of AUC imatinib. The binding of a metabolite with blood plasma proteins is similar to that of imatinib.

    Imatinib and its main metabolite together constitute about 65% of circulating radioactivity (AUC(0-48)). This amount of circulating radioactivity is consistent with the number of secondary metabolites.

    results in vitro studies have shown that isoenzyme CYP3A4 is the main enzyme of cytochrome P450b which catalyzes the metabolism of imatinib. From the list of drugs that can potentially be used simultaneously with imatinib (paracetamol, acyclovir, allopurinol, amphotericin B, cytarabine, erythromycin, fluconazole, hydroxyurea, norfloxacin, penicillin V), only erythromycin (concentration of half maximal inhibition (IC50) 50 μM) and fluconazole (IC50 = 118 μM) inhibited imatinib metabolism to a clinically significant extent.

    AT in vitro research imatinib is a competitive inhibitor of marker substrates of isoenzymes CYP2C9, CYP2D6 and CYP3A4/5. The significance of the binding activity of the inhibitor with the reaction substrate (Ki) in human liver microsomes was 27, 7.5 and 7.9 μmol / L, respectively. FROMmOh imatinib in the blood plasma in patients - 2-4 μmol / l, therefore it is possible to inhibit the metabolism of simultaneously taken with imatinib drugs, the metabolism of which is mediated by isoenzymes CYP2D6 and / or CYP3A4/5. Imatinib does not interfere with the metabolism of fluorouracil, but as a result of competitive inhibition of the isoenzyme CYP2C8 (TOi = 34.7 μM) blocks the metabolism of paclitaxel. This value of Ki is much higher than the expected concentration of imatinib in the blood plasma in patients, respectively simultaneous reception as fluorouracil. and paclitaxel interactions are not expected.

    Excretion

    Based on the data obtained in determining the amount of radioactive imatinib after ingestion, labeled with a 14C label, about 81% of its accepted dose is excreted from the body within 7 days (68% through the intestine and 13% by the kidneys).In an unchanged form, about 25% of the dose is output (20% through the intestine and 5% by the kidneys), the remaining amount - in the form of metabolites. The half-life of imatinib is about 18 hours. When taking repeated doses of imatinib once a day, its pharmacokinetic parameters do not change, a Css Imatinib exceeds the initial value by 1.5-2.5 times.

    Pharmacokinetics in specific patient groups

    Pharmacokinetics in patients with gastrointestinal stromal tumors

    In patients with gastrointestinal stromal tumors (GISO) AUC Imatinib in the equilibrium state is 1.5 times higher than that in patients with CML when taking a dose of 400 mg per day. Based on a preliminary analysis of the pharmacokinetic data in patients with GISO, three variables (albumin, leukocytes and bilirubin) were identified that had a statistically significant relationship with the pharmacokinetics of imatinib. Reducing the albumin concentration and increasing the number of leukocytes leads to a decrease in the clearance of imatinib. However, this phenomenon is not sufficiently expressed in order to correct the dose of imatinib. In this population, the presence of liver metastases can lead to liver failure and slow the metabolism of imatinib.

    Other patient populations

    Based on the analysis of pharmacokinetic data in patients with CML, age does not significantly affect the volume of distribution (Vd Imatinib (in patients over 65 years of age Vd increases by 12%). This change is not considered clinically significant.

    For patients with a body weight of 50 kg, the average clearance value of imatinib is about 8.5 l / h, and for patients with a body weight of 100 kg, about 11.8 l / h. However, these differences are not significant and do not require correction of the dose depending on the patient's body weight.

    The pharmacokinetics of imatinib does not depend on sex.

    Changes in clearance values ​​and Vd Imatinib with simultaneous use with other medicines are unimportant and do not require dose changes.

    Pharmacokinetics in children and adolescents under the age of 18

    In children and adolescents under the age of 18, as in adults, imatinib quickly absorbed after ingestion. AUC in this group of patients in a dose range of 260 and 340 mg / m2/ day is similar to that in adults in the dose range of 400 mg and 600 mg, respectively. When comparing values ​​in children and adolescents AUC(0-24) on the 1 st and 8 th days after repeated intake of imatinib in a dose of 340 mg / m2/ day, the increase in the values ​​of this indicator is 1.7 times, which indicates the cumulation of imatinib.Based on the combined population pharmacokinetic analysis in children with hematological diseases have been shown that the clearance of imatinib is directly proportional to the surface area of ​​the body, other demographic parameters (age, body weight and body mass index) have no clinically significant effect on the imatinib exposure.

    Infringement of function of retail bodies

    Imatinib and its metabolites are slightly excreted through the kidneys.

    When imatinib is used in patients with mild or moderate renal dysfunction (CK> 30 ml / min), the imatinib exposure in blood plasma is increased by 1.5-2.0 times in comparison with patients with normal renal function, which corresponds to an increase in the concentration of acidic alpha-glycoproteins in 1,5 times (the main proteins of blood plasma, which bind with imatinib). Because the imatinib is slightly excreted by the kidneys, the clearance of free imatinib does not depend on the presence of renal dysfunction.

    Correlation between the exposure of imatinib and the severity of liver function abnormalities was not revealed.

    Indications:

    - First identified Ph+ CML in children and adults;

    - Rh+ CML in the chronic phase if previous interferon alpha therapy is ineffective or in the accelerated phase, or blast crisis in children and adults;

    - first diagnosed positive for the Philadelphia chromosome acute lymphoblastic leukemia in children and adult patients in combination with chemotherapy;

    - recurrent or refractory Ph+ ALL in adults as a monotherapy;

    - myelodysplastic / myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements in adult patients;

    - SM in adult patients with lack of D816V c-Kit mutation or with unknown c-Kit mutational status;

    - HES and / or HEL in adults with positive or negative abnormal FIP1L1-PDGFR alpha-tyrosine kinase:

    - Inoperable and / or metastatic malignant GISO positive for c-Kit (Cd 117) in adult patients;

    - Adjuvant therapy GISO positive by c-Kit (Cd 117) in adult patients;

    - inoperable, relapsing and / or metastatic swelling dermatofibrosarcoma in adult patients.

    Contraindications:

    Hypersensitivity to imatinib or any other component of the drug.

    Pregnancy and the period of breastfeeding.

    Child age (effectiveness and safety not established):

    - up to 1 year in patients with Ph+ acute lymphoblastic leukemia;

    - up to 2 years in patients with Ph + chronic myeloid leukemia:

    - up to 18 years for other indications.

    Carefully:

    Patients with severe hepatic insufficiency, with impaired renal function of severe severity, cardiovascular disease or in the presence of risk factors for heart failure, as well as in the regular procedure of hemodialysis.

    When used simultaneously with preparations inhibiting the isoenzyme CYP3A4, strong isoenzyme inducers CYP3A4: with preparations that are substrates of isoenzyme CYP3A4. paracetamol, warfarin (see section "Interaction with other drugs").

    Pregnancy and lactation:

    Women of childbearing age should be treated with effective methods of contraception during therapy with Imatinib-Actavis and, at least, within 3 months afterwards.

    Pregnancy

    Data on the use of imatinib in pregnant women are limited.Studies on animals have shown toxic effects on reproductive function, but the potential risk to the fetus is not yet known. The intake of Imatinib-Actavis during pregnancy is contraindicated. If the drug is used during pregnancy, the patient should be warned about the risk of fetal damage.

    Breast-feeding

    Data on the isolation of imatinib in breast milk are limited. Observations of two breastfeeding women revealed the presence of imatinib and its active metabolite in breast milk. One patient was monitoring the ratio of imatinib concentration in breast milk to imatinib plasma concentrations. It was found that for imatinib this value was 0.5, and for the metabolite it was 0.9, which confirms the high ability of excretion of the metabolite into breast milk. Considering the concentration of both imatinib. both the metabolite and the maximum amount of breast milk eaten by the baby, a negligible total effect on the newborn is expected (approximately 10% of the therapeutic dose). However, since the effect of a slight effect of imatinib on a newborn is not known,taking the drug Imatinib-Aktavis, you should stop breastfeeding.

    Fertility

    In animal studies, there was no evidence of impaired fertility. Studies on the effects on fertility and gametogenesis in patients taking imatinib, was not carried out. Patients on fertility when taking Imatinib-Aktavis should consult with the doctor in charge.

    Dosing and Administration:

    Inside. The drug should be taken with food. drinking a full glass of water to reduce the risk of developing gastrointestinal disorders. Doses of 400 mg and 600 mg per day should be taken in 1 dose; The daily dose of 800 mg should be divided into 2 doses - 400 mg in the morning and in the evening.

    Patients who are not able to swallow the whole capsule, for example, children, the drug can be taken in a diluted form; the contents of the capsules are diluted with water or apple juice.

    Treatment with the drug is carried out as long as the clinical effect remains.

    Positive for the Philadelphia chromosome chronic myeloid leukemia

    With CML, the recommended dose of Imatinib-Actavis depends on the phase of the disease.In the chronic phase of CML, the dose is 400 mg per day: during the acceleration phase and with a blast crisis, 600 mg per day. The drug should be taken 1 time per day.

    In the absence of severe side effects and neutropenia or thrombocytopenia not associated with leukemia, a dose increase from 400 mg to 600 mg or up to 800 mg in patients in the chronic phase of the disease and from 600 mg to 800 mg per day in patients in the accelerated phase and with a blast cry. This increase in dose may be necessary in the progression of CML (any stage), in the absence of a satisfactory hematologic response after 3 months of treatment, cytogenetic response at 12 months of therapy or loss previously achieved hematologic and / or cytogenetic response.

    Calculation of the dosing regimen in children older than 1 year is based on the surface area of ​​the body. The recommended daily dose is 340 mg / m2. The total daily dose in children should not exceed 600 mg. The daily dose of the drug is recommended to be taken simultaneously or divided into 2 equal doses - in the morning and in the evening.

    Ph + acute lymphoblastic leukemia in adults

    The recommended dose of Imatinib-Actavis is 600 mg per day.

    In adult patients with recurrent or refractory Ph + acute lymphoblastic leukemia the recommended dose is 600 mg per day.

    Myelodysplastic / myeloproliferative diseases

    The recommended dose of Imatinib-Actavis is 400 mg per day.

    With CM with the absence of D816V c-Kit mutation the recommended dose of Imatinib-Actavis is 400 mg per day.

    With an unknown c-Kit mutation status and the insufficient effectiveness of previous therapy, the recommended dose is 400 mg per day.

    With CM, due to abnormal FIP1L1-PDGFR alpha-tyrosine kinase, formed as a result of the fusion of the genes Fip like1 and PDGFR the recommended initial dose is 100 mg per day. With insufficient effectiveness and no significant side effects, an increase in the dose to 400 mg per day is possible.

    With HPS / HAL in adults, the recommended dose is 400 mg per day. In patients with HES / HAL. due to abnormal FIP1L1-PDGFR alpha-tyrosine kinase, the recommended initial dose is 100 mg per day. With insufficient effectiveness and no significant side effects, an increase in the daily dose to 400 mg per day is possible. Treatment with the drug is carried out until then. while the clinical effect remains.

    With inoperable and / or metastatic malignant GISO c-Kit positive (CD 117) the recommended dose is 400 mg per day.In the absence of side effects and insufficient response to treatment, an increase in the daily dose from 400 mg per day to 600 mg per day or 800 mg per day is possible.

    If signs of disease progression appear, Imatinib-Actavis should be discontinued.

    With adjuvant therapy GISO positive for c-Kit (CD 1/7) the recommended dose is 400 mg per day. The minimum duration of treatment is 3 years. The optimal duration of treatment is not established.

    Inoperable, recurrent and / or metastatic swelling dermatofibrosarcoma in adults

    The recommended dose of Imatinib-Actavis is 800 mg per day.

    Patients with impaired hepatic function

    Because the imatinib is metabolized. mainly in the liver, in patients with mild, moderate or severe impairment of liver function, Imatinib-Actavis should be used at a minimum daily dose of 400 mg. With the development of undesirable toxic effects, the dose of the drug should be reduced. The drug should be administered with caution to patients with severe hepatic impairment.

    Patients with impaired renal function

    Kidneys do not play a significant role in the excretion of imatinib and its metabolites. In patients with impaired renal function or in patients requiring systematic hemodialysis, treatment with Imatinib-Actavis should be started with a minimum effective dose of 400 mg once daily, taking care.

    If Imatinib-Aktavis is intolerant, the initial dose of the drug can be reduced, with insufficient effectiveness - increased.

    Elderly patients

    Older patients do not need to adjust the dosage regimen of the drug.

    Correction of the dosing regimen with the development of non -hematological side effects of the drug

    With the development of any serious non-hematologic side effect associated with taking the drug, therapy should be discontinued until the situation resolves. The treatment can then be resumed at a dose that depends on the severity of the observed side effect.

    With an increase in the concentration of bilirubin and an increase in the activity of "hepatic" liver transaminases in the blood serum 3 and 5 times higher than the upper limit of the norm (VGP)treatment with the drug should be temporarily suspended until the concentration of bilirubin is reduced to less than 1.5xVGN and the activity of "hepatic" transaminases to less than 2.5xVGN.

    Therapy with Imatinib-Actavis is resumed at a lower daily dose: in adults, the dose is reduced from 400 mg to 300 mg per day or from 600 mg to 400 mg per day, or from 800 mg to 600 mg per day: in children, from 340 to 260 mg / m2 per day.

    Correction of the dosing regimen with the development of serious side effects from the hematopoiesis system (severe thrombocytopenia, neutropenia)

    In the event of neutropenia and thrombocytopenia, a temporary withdrawal of the drug or a decrease in its dose is required, depending on the severity of these undesirable phenomena.

    When SM and FSC / HAL, the anomalous F1P1L1-PDUFR alpha-tyrosine kinase (the initial dose of the drug is 100 mg), if the absolute number of neutrophils is less than 1000 / μL and / or the platelet count is less than 50,000 / μL, it is recommended:

    1. cancel the drug until the absolute number of neutrophils is ≥1500 / μL and platelets ≥75,000 / μL;

    2. resume treatment with the drug in a dose used before the interruption of therapy.

    In the chronic phase of CML in children and adults (initial daily intake for adults - 400 mg, for children - 340 mg / m2), malignant GISO, myelodysplastic / myeloproliferative diseases, SM and HES / HAL in adults (the initial daily intake for adults is 400 mg), if the absolute number of neutrophils is less than 1000 / μL and / or the platelet count is less than 50,000 / μL, it is recommended:

    1. cancel the drug until the absolute number of neutrophils is ≥1500 / μL and platelets ≥75,000 / μL;

    2. resume treatment with the drug in a dose used before the interruption of therapy.

    3. If the number of neutrophils is less than 1000 / μL and / or the number of platelets is less than 50,000 / μL, repeat the actions indicated in point 1, and then resume treatment with the drug in a reduced dose of 300 mg / day (in children - 260 mg / m2/ day).

    AT phase of acceleration and power crisis of CML in children and adults and with Ph + acute lymphoblastic leukemia in adult patients (initial daily dose for adults - 600 mg, for children - 340 mg / m2) if the absolute number of neutrophils is less than 500 / μL and / or the platelet count is less than 10,000 / μL after one or more months of treatment, it is recommended:

    1. check whether cytopenia is a consequence of leukemia (bone marrow examination);

    2. If cytopenia is not associated with leukemia, reduce the daily dose of the drug to 400 mg (in children - 260 mg / m2);

    3. If cytopenia persists for 2 weeks, reduce the daily dose to 300 mg (in children - 200 mg / m2);

    4. If cytopenia persists for 4 weeks and its association with leukemia is not confirmed, discontinue the drug until the absolute number of neutrophils becomes at least 1000 / μL and platelets not less than 20,000 / μL; then resume treatment with the drug at a daily dose of 300 mg (in children - 200 mg / m2).

    When inoperable, recurrent and / or metastatic swelling dermatofibrosarcoma (initial dose of 800 mg) in the case of a decrease in the absolute number of neutrophils <1000 / μL and / or the number of platelets <50000 / μL is recommended:

    1. cancel the drug until the absolute number of neutrophils is ≥1500 / μL and platelets ≥75,000 / μL;

    2. resume treatment with the drug in a dose of 600 mg.

    If the number of neutrophils is less than 1000 / μL and / or the platelet count is less than 50,000 / μL, repeat the actions indicated in point 1. and then resume treatment with the drug in a reduced dose of 400 mg.

    Side effects:

    Patients with advanced malignant tumors can have many medically aggravated conditions,which make it difficult to assess the causal relationship of the adverse reaction with imatinib due to the presence of a variety of symptoms associated with the ongoing disease, its progression and simultaneous administration of several drugs.

    In clinical trials of CML due to adverse reactions, 2.4% of patients with a newly diagnosed disease discontinued treatment. 4% of patients with the disease in the chronic phase with the ineffectiveness of previous therapy with interferon. 4% of patients in the aze of acceleration with ineffectiveness of previous therapy with interferon and 5% of patients in the phase of blast crisis with ineffectiveness of previous therapy with interferon. In clinical studies of imatinib during treatment of GISD due to adverse reactions, 4% of patients stopped taking it.

    The profile of adverse reactions differed for two indications. In patients with CML, myelosuppression is more common than in patients with GIS. which is probably due to the presence of the disease itself. In 7 (5%) patients with inoperable and / or metastatic GISO, bleeding at 3/4 was observed in the general toxicity scale: 3 patients with gastrointestinal bleeding.3 patients with intracelach hemorrhage, both types of bleeding were observed in 1 patient. Gastrointestinal swelling can be a source of gastrointestinal bleeding (see section "Special instructions"). Gastrointestinal and intratumoral bleeding can be serious and sometimes fatal. The most frequent adverse events (> 10%) associated with imatinib. in both cases: mild nausea, vomiting, diarrhea, abdominal pain, weakness, myalgia, muscle cramps, rash. A frequent adverse reaction in all studies was superficial edema, mainly described as periorbital edema or edema of the lower limbs. However, these edemas were rarely severe and were eliminated by taking diuretics, and by taking other appropriate measures to eliminate edema or reduce the dose of imatinib.

    When taking imatinib in combination with high doses of chemotherapy in patients with Ph+ ALL caused temporary manifestations of hepatotoxicity in the form of increased activity of "hepatic" transaminases and hyperbilirubinemia.

    There may be several adverse reactions,described collectively as "fluid retention" in the body: pleural effusion, ascites, pulmonary edema and a rapid increase in body weight with or without superficial edema. These reactions, as a rule, can be eliminated by the temporary cancellation of imatinib, taking diuretics, or taking other appropriate measures to eliminate edema. However, some of the above reactions may be severe or life threatening. There have been reports of fatal cases in patients with blast crisis, who have had a complex of diseases in the history of the disease: pleural effusion, congestive heart insufficiency and renal insufficiency. There were no specific features in the imatinib safety profile for the infant population.

    In clinical trials, the following adverse events were noted in the patients listed below in terms of organs and systems, indicating the frequency of their occurrence: very often (≥1/10), often (≥1 / 100, <1/10), infrequently (≥1 / 1000, <1/100), rarely (≥1 / 10,000, <1/1000), very rarely (<1/10 000), the frequency is unknown (can not be determined from available data).

    In each subgroup, unwanted reactions are listed in order of frequency of occurrence, the most common are the first.

    Infectious and parasitic diseases: infrequent herpes zoster, herpes simplex, nasopharyngitis, pneumonia1, sinusitis, inflammation of the subcutaneous tissue, upper respiratory infections, influenza, urinary tract infections, gastroenteritis, sepsis: rarely - mycoses.

    Benign, malignant and unspecified neoplasms (including polyps and cysts): rarely - tumor lysis syndrome.

    From the side of the blood and lymphatic system: very often - neutropenia, thrombocytopenia, anemia: often - pancytopenia, febrile neutropenia: infrequently thrombocythemia, lymphopenia, oppression of bone marrow hematopoiesis, eosinophilia, lymphadenopathy; rarely - hemolytic anemia.

    From the side of metabolism and nutrition: often - anorexia; infrequently - hypokalemia. increased appetite, hypophosphatemia. decreased appetite, dehydration, gout, hyperuricemia. hypercalcemia. hyperglycemia. hyponatremia: rarely hyperkalemia, hypomagnesemia.

    Disorders of the psyche: often - insomnia; infrequently - depression, decreased libido, anxiety; rarely confusion.

    From the nervous system: very often - headache2; often - dizziness, paresthesia, impaired taste,hypoesthesia: infrequently - migraine, drowsiness, fainting, peripheral neuropathy, memory impairment, sciatica, restless legs syndrome, tremor, hemorrhagic stroke; rarely - increased intracranial pressure, convulsions, optic neuritis.

    From the side of the organ of vision: often - edema of the eyelids, increased tearing, conjunctival hemorrhage, conjunctivitis, dry eye syndrome, blurred vision; infrequent eye irritation, eye pain, orbital edema, bleeding in the sclera of the eye, retinal hemorrhages, blepharitis, macular edema; rarely - cataract, glaucoma, edema of the optic disc.

    From the side of the hearing organ and labyrinthine disorders: infrequently - vertigo, noise in the ears, hearing loss.

    From the heart: infrequent - palpitations, tachycardia, congestive heart failure3, pulmonary edema: rarely - arrhythmias, atrial fibrillation, sudden cardiac arrest, myocardial infarction, angina pectoris, pericardial effusion.

    From the side of the vessels: often - "tides"4, hemorrhage4; infrequently - increase of arterial pressure, hematomas, subdural hematoma, cooling of limbs, lowering of arterial pressure, Raynaud's syndrome.

    FROMabout the respiratory system, chest, mediastinum: often shortness of breath, epistaxis, cough: infrequent pleural effusion5, pain in the pharynx or larynx, pharyngitis: rarely - pleural pain, pulmonary fibrosis, pulmonary hypertension, pulmonary hemorrhage.

    From the digestive system: very often - nausea, diarrhea, vomiting, dyspepsia, abdominal pain6: often - flatulence, bloating, gastroesophageal reflux, constipation, dry mouth, gastritis: infrequently - stomatitis, ulceration of the oral mucosa, gastrointestinal bleeding7, belching, melena, esophagitis, ascites, stomach ulcer, vomiting of blood, cheilitis. dysphagia, pancreatitis: rarely - colitis, paralytic / obturation intestinal obstruction, inflammation of the intestine.

    From the liver and bile ducts: often - increased activity of "liver" transaminases; infrequently hyperbilirubinemia. hepatitis, jaundice; rarely liver failure9, necrosis of the liver9.

    From the skin and subcutaneous tissues: very often - periorbital edema, dermatitis, eczema, skin rash; often - itchy skin, puffiness of the face, dry skin, erythema, alopecia, night sweats,photosensitivity reaction; infrequent - pustular rash, bruising, increased sweating, urticaria, ecchymosis, increased predisposition to hematoma formation, hypotrichosis, skin hypopigmentation, exfoliative dermatitis, nail damage, folliculitis, petechiae, psoriasis, purpura, hyperpigmentation of skin, bullous rash; rare - acute febrile neutrophilic dermatosis (Sweet syndrome), nail color change, angioedema, vesicular rash, erythema multiforme, leukoclastic vasculitis, Stevens-Johnson syndrome, acute generalized pustular exanthema, drug rash with eosinophilia and systemic symptoms (DRESS).

    From the musculoskeletal system and connective tissue: very often muscle spasms and cramps, musculoskeletal pain (including myalgia, arthralgia, bone pain8); often - swelling of joints: infrequent - stiffness of muscles and joints; rarely - muscular weakness, arthritis, rhabdomyolysis / myopathy; frequency is unknown - growth retardation in children.

    From the urinary system: infrequently - kidney pain, hematuria, acute renal failure, frequent urination.

    Co side of the reproductive system and mammary glands: infrequently - gynecomastia, erectile dysfunction, menorrhagia. violation of the menstrual cycle, sexual dysfunction, pain in the nipples, enlargement of the mammary glands, swelling of the scrotum; rarely bleeding from the cyst of the yellow body / ovary.

    General disorders and disorders at the site of administration: very often - fluid retention, swelling, increased fatigue; often - weakness, fever, anasarca, chills, trembling; infrequently - chest pain, general malaise.

    From the laboratory indicators: very often - weight gain; often - decreased body weight; infrequently - an increase in serum creatinine, activity of creatine phosphokinase, lactate dehydrogenase, alkaline phosphatase; rarely - increased activity of amylase in blood plasma.

    1 - Pneumonia was most often observed in patients with CML in the phase of acceleration, blast crisis and with inoperable and / or metastatic gastrointestinal malignant tumors.

    2 - Headache was most often noted in patients with inoperable and / or metastatic gastrointestinal tumors.

    3 - Undesirable heart events, including congestive heart failure, were more common in patients with CML in the accelerated phase and with blast crisis compared to patients with CML in the chronic phase (duration of follow-up is 1 year).

    4- "Tides" were most often observed in patients with inoperable and / or metastatic malignant stromal tumors of the gastrointestinal tract: bleeding (haematomas, hemorrhages) was most often observed in patients with CML in the phase of acceleration, blast crisis and with inoperable and / or metastatic malignant stromal tumors of the gastrointestinal tract .

    5 - Pleural effusion was more often observed in patients with gastrointestinal and CML stromal tumors in the phase of acceleration and with blast crisis in comparison with patients with CML in the chronic phase.

    6/7- Abdominal pain and gastrointestinal hemorrhage were most often observed in patients with inoperable and / or metastatic gastrointestinal malignant tumors.

    8 - Musculoskeletal pain and related adverse events (in myalgia of myalgia, arthralgia, bone pain) were more frequent in patients with CML than in patients with inoperable and / or metastatic gastrointestinal malignant tumors.

    9 - Fatal cases of hepatic insufficiency and liver necrosis have been reported.

    In the application of imatinib in clinical practice, as well as in additional clinical studies, the adverse reactions listed below were noted. Since information on adverse reactions has been obtained in the form of spontaneous reports from patients whose population size is not known accurately, it is not always possible to establish the incidence of adverse reactions or the relationship between imatinib use and these adverse reactions.

    Post-registration application experience

    Benign, malignant and unspecified neoplasms (including cysts and polyps): frequency unknown - bleeding from the tumor / tumor necrosis.

    From the immune system: frequency unknown - anaphylactic shock.

    Co side of the nervous system: frequency unknown - edema of the brain.

    From the side of the organ of vision: frequency unknown - hemorrhage in the vitreous.

    From the heart: frequency is unknown - pericarditis, cardiac tamponade.

    From the side of the vessels: frequency unknown - thrombosis / embolism.

    From the respiratory, thoracic, mediastinal: frequency unknown - acute respiratory failure1, interstitial lung disease.

    From the gastrointestinal tract: rarely - vascular ectasia of the antrum of the stomach (GAVE-syndrome); frequency unknown - paralytic / obstructive intestinal obstruction, perforation of the gastrointestinal tract, diverticulum pt.

    From the skin and subcutaneous tissues: frequency unknown - palmar-plantar erythrodysesthesia; lichenoid keratosis, lichen planus; toxic epidermal necrolysis; drug rash with eosinophilia and systemic symptoms (DRESS-cindre).

    From the osteomuscular and connective tissue: frequency unknown - Avascular necrosis / necrosis of the head of the femur: growth retardation in children.

    1 - There are some reports of the development of severe acute respiratory failure with a fatal outcome in patients with severe infectious diseases, severe neutropenia and other serious concomitant diseases.

    Description of individual adverse reactions

    Inhibition of hematopoiesis

    In patients with CML, cytopenia was observed in all studies, especially neutropenia and thrombocytopenia, its frequency was higher when taking high doses of imatinib> 750 mg (phase I). However, the frequency of cytopenia also reliably depended on the stage of the disease. Frequency of neutropenia 3 or 4 degrees (absolute number neutrophils <1.0х109/ l) and thrombocytopenia (the number of platelets <50x109/ l) was 4 and 6 times higher in the blast crisis phase and in the acceleration phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) compared with the newly diagnosed CML in the chronic phase (16.7% neutropenia and 8.9% thrombocytopenia). In patients with newly diagnosed CML in the chronic phase of grade 4 neutropenia (absolute number of neutrophils <0.5x109/ l) and thrombocytopenia (number of platelets <10x109/ l) were observed in 3.6% and less than 1% of patients, respectively. The median duration of episodes of neutropenia and thrombocytopenia usually ranged from 2 to 3 weeks and from 3 to 4 weeks, respectively. These undesirable phenomena, as a rule, are stopped by a decrease in the dose of imatinib. or temporary cancellation of his admission, but in rare cases they may require a complete cancellation of imatinib administration or its cancellation for a long time.In children with CML, the most common toxic effect was observed in the form of grade 3 or 4 cytopenia, including neutropenia, thrombocytopenia and anemia. These reactions mainly occurred in the first months of treatment.

    In general, oppression of hematopoiesis with imatinib in patients with CML was reversible and in most cases did not require the abolition of imatinib or the reduction of its dose. The abolition of imatinib was required in a small number of cases. Also observed were such phenomena as pancytopenia, lymphopenia and oppression of hematopoiesis.

    In studies in patients with inoperable and / or metastatic malignant GISO, anemia of grade 3 and 4 was reported in 5.4% and 0.7% of patients, respectively. This phenomenon, but at least in some patients, may be associated with bleeding in the gastrointestinal tract or intracutaneous hemorrhage. Neutropenia of grade 3 and 4 was observed in 7.5% and 2.7% of patients, respectively, and grade 3 thrombocytopenia in 0.7% of patients. There were no patients with thrombocytopenia of the 4th degree. The decrease in the number of leukocytes and neutrophils occurred mainly during the first six weeks of therapy, with the establishment of relatively stable values ​​after a given period of time.

    Biochemical indicators of blood

    A significant increase in the activity of hepatic transaminases (<5%) or an increase in bilirubin concentration (<1%) was observed in patients with CML and, as a rule, these adverse events were resolved after lowering the dose of imatinib or interrupting treatment (the median duration of these adverse events was approximately one week). The treatment was canceled or interrupted for a long time because of a deviation from the norm of laboratory tests of liver function in less than 1% patients with CML. An increase in alanine aminotransferase activity of grade 3 or 4 was observed in 6.8% of patients with GISD, and an increase in activity of aspartate aminotransferase of grade 3 or 4 in 4.8%. The increase in bilirubin concentration was less in 3% of patients.

    There have been reports of the development of cytolytic and cholestatic hepatitis and liver failure, in some cases fatal, including the case of a patient taking high doses of paracetamol.

    Severe adverse events on the part of the respiratory system

    Severe (sometimes fatal) adverse events were noted with imatinib: acute respiratory failure, pulmonary hypertension, interstitial lung disease and pulmonary fibrosis.The concomitant pathology of the cardiovascular and respiratory systems can aggravate the severity of the undesirable phenomenon.

    Overdose:

    The experience with imatinib in doses exceeding the therapeutic dose is limited. There was reported an imatinib overdose in spontaneous reports and literary sources. In general, the outcome of cases of imatinib overdose was favorable (there was an improvement in the condition of patients).

    Symptoms of an overdose in adults depending on the dose are as follows: nausea, vomiting, diarrhea, rash, erythema, swelling, swelling (mostly facial), increased fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache pain, loss of appetite.

    When imatinib was taken in a dose of 1800-3200 mg (the highest dose was 3200 mg per day for 6 days), weakness, myalgia, increased activity of creatine phosphokinase (CK) in the blood, bilirubin concentration, gastrointestinal pain were noted.

    With imatinib once in a dose of 6400 mg (information from a published source), the patient developed nausea, vomiting, abdominal pain, hyperthermia, facial edema, a decrease in the number of neutrophils and an increase in the activity of "liver" transaminases.

    When taking imatinib in a dose of 8-10 g, vomiting and gastrointestinal pain were noted once.

    Symptoms of overdose in children and adolescents: in a male child at the age of 3 years with imatinib once taken in a dose of 400 mg, vomiting, diarrhea and anorexia. In another case, in a male child at the age of 3 years with a single dose of imatinib, 980 mg, a decrease in the number of leukocytes and diarrhea was observed.

    Treatment: recommended medical supervision and symptomatic therapy.

    Antidote to imatinib is unknown.

    Interaction:

    Medicinal products, which can increase the concentration of imatinib in the blood plasma

    With the simultaneous use of imatinib with isozyme inhibitory drugs CYP3A4 cytochrome P450 (eg, HIV protease inhibitors such as indinavir, lopinavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungal agents, including ketoconazole, itraconazole, posaconazole, voriconazole; some macrolides, such as erythromycin, clarithromycin and telithromycin), possibly slowing the metabolism of imatinib and increasing its concentration in the blood plasma.With the simultaneous administration of imatinib and a single dose of ketoconazole (inhibitor of isoenzyme CYP3A4) in healthy volunteers, there was a significant increase in the degree of exposure of imatinib to the body (mean Cmax and AUC increased by 26% and 40% respectively). Caution is necessary when combined with imatinib with isozyme inhibitor drugs CYP3A4.

    Medicines that can reduce the concentration of imatinib in the blood plasma

    Simultaneous use of drugs that are inducers of isoenzyme CYP3A4 (eg, dexamethasone, phenytoin, phosphenytoin, rifampicin, phenobarbital or preparations of St. John's wort, carbamazepine, oxcarbazepine, primidon), can significantly reduce the effects of imatinib, potentially increasing the risk of no therapeutic effect. The previous multiple administration of rifampicin at a dose of 600 mg before taking a single dose of imatinib 400 mg led to a decrease in the values ​​of Cmax and AUC(0-͚) at least 54% and 74% compared with values ​​in patients who did not take rifampicin. A similar result was observed in patients with malignant glioma who received imatinib while receiving inducers of liver enzymes, including antiepileptic drugs, such as carbamazepine, oxcarbamazepine and phenytoin. Value AUC Imatinib in the blood plasma was reduced by 73% compared with the values ​​in patients not taking drugs of this group. Avoid simultaneous administration of rifampicin or other strong isoenzyme inducers CYP3A4 with imatinib.

    Medicines, the concentration in the blood plasma of which can vary with the simultaneous administration of imatinib

    With the simultaneous use of imatinib and simvastatin, there is an increase in Cmax and AUC simvastatin (substrate isoenzyme CYP3A4) in 2 and 3.5 times, respectively, which is a consequence of inhibition of the isoenzyme CYP3A4 imatinib. It is advisable to use caution when using imatinib and preparations that are substrates of the isoenzyme CYP3A4 and having a narrow breadth of therapeutic effect (for example, ciclosporin, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel and quinidine).

    Imatinib may increase serum concentrations of other drugs metabolized by isoenzyme CYP3A4 (eg, triazolo-benzodiazepines, dihydropyridine, "slow" calcium channel blockers, some HMG-CoA reductase inhibitors, also called statins, etc.).

    Because of the increased risk of bleeding with imatinib (eg, hemorrhage), patients who require anticoagulation therapy should be treated with low-molecular-weight heparin derivatives or heparin, replacing coumarin derivatives such as warfarin. Elongation of prothrombin time was observed when combined with warfarin. When used simultaneously with coumarin derivatives, short-term monitoring of prothrombin time at the beginning and end of therapy with imatinib, as well as changes in the dosage regimen of imatinib, is necessary.

    In vitro imatinib inhibits isoenzyme CYP2D6 cytochrome P450 at the same concentrations in which it inhibits the isoenzyme CYP3A4.

    When applying imatinib in a dose of 400 mg 2 times a day, together with metoprolol. substrate of isoenzyme CYP2D6, there is a moderate decrease in metoprolol metabolism, accompanied by an increase in CmOh and AUC approximately by 23% (a reliable interval of 90%). It is not necessary to change the dosing regimen when imatinib is taken with isoenzyme substrates CYP2D6, However, care must be taken when taking isoenzyme substrates CYP2D6, With a narrow breadth of therapeutic effect, such as metoprolol. For patients receiving metoprolol. careful observation is necessary. In vitro imatinib inhibits the O-glucoronidation of acetaminophen / paracetamol (inhibition constant Ki 58,5 μM). However, the use of imatinib (400 mg / day for 8 days) with acetaminophen / paracetamol (a single dose of 1000 mg on the eighth day) in patients with CML did not lead to a change in the pharmacokinetics of acetaminophen / paracetamol. The pharmacokinetics of imatinib did not change with a single admission of acetaminophen / paracetamol. Information on the pharmacokinetics or safety of simultaneous application of imatinib in doses> 400 mg / day with acetaminophen / paracetamol or prolonged simultaneous use of acetaminophen / paracetamol and imatinib is not available. This inhibition was not observed in vivo after taking imatinib in a dose of 400 mg and paracetamol in a dose of 1000 mg. Higher doses of imatinib and paracetamol have not been investigated.

    Caution should be exercised while taking high doses of imatinib and paracetamol.

    In patients undergoing thyroidectomy and receiving hormone replacement therapy with levothyroxine sodium, it is possible to reduce its plasma concentration when combined with imatinib (see section "Special instructions"). Therefore, we recommend caution when taking these medications together. The mechanism of the observed interaction is currently unknown.

    The issue of drug interaction between imatinib and chemotherapy drugs in patients with Ph+ ALL. There are also reports that there is an increase in hepatotoxicity with simultaneous administration of imatinib with L-asparhinase. Caution should be exercised when using imatinib and chemotherapeutic drugs in conjunction with a possible increase in the risk of developing complications such as hepatotoxicity. myelotoxicity, etc. When combining imatinib and regimens of chemotherapy that can potentially cause a violation of liver function, liver function monitoring should be provided.There are reports of the development of liver damage in the joint use of imatinib and asparaginase.

    Imatinib also inhibits isoenzymes CYP2C9 and CYP2C19 in vitro.

    Special instructions:

    The drug should be treated only under the supervision of a doctor who has experience with antitumor drugs.

    When handling the drug, avoid contact with the skin and eyes, as well as inhaling the powder of the drug.

    During therapy with the drug and, at least 3 months after, patients should use reliable methods of contraception.

    With simultaneous admission with other medicinal products, the development of interaction is possible. Caution should be taken with the drug with inhibitors of HIV proteases, antifungal drugs from the group of azoles, some macrolides (see section "Interaction with other medicinal products"), substrates CYP3A4 with a narrow therapeutic index (for example, ciclosporin, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section "Interaction with other medicinal products").

    Simultaneous administration of imatinib and isozyme-inducing drugs CYP3A4 (eg, dexamethasone, phenytoin, carbamazepine, rifampicin, phenobarbital or medicines from herbal remedies of St. John's wort) can significantly reduce the effect of imatinib on the body, potentially increasing the risk of a therapeutic response to treatment.

    Therefore, it is necessary to avoid simultaneous reception of strong isoenzyme inducers CYP3A4 and Imatinib-Actavis preparation (see section "Interaction with other medicinal products").

    Childhood

    Experience with imatinib in children with ALL is less than 1 year, the experience with imatinib in children with CML younger than 2 years is limited, experience with imatinib for other indications is limited in patients under 18 years of age. Long-term effects of prolonged exposure to imatinib for growth in children are not known, but since there are reports of growth retardation, careful growth control is recommended in children receiving imatinib. In addition, in the post-marketing period, separate reports were received on cases of vascular ectasia of the antrum of the stomach (GAVE-syndrome), a rare cause of gastrointestinal bleeding, registered in patients with CML. ALL and other diseases. It is necessary to monitor the state of the gastrointestinal tract in patients with metastatic malignant gastrointestinal stromal tumors (abdominal pain, gastrointestinal bleeding, constipation, etc.) at the beginning and throughout the therapy with imatinib. If necessary, consider the possibility of reversing therapy with the drug.

    Fluid retention

    The incidence of serious symptoms of fluid retention (pleural effusion, edema, pulmonary edema, ascites, superficial edema) was approximately 2.5% of patients with first detected by CML. host imatinib. When imatinib is used in 1-2% of cases, a marked fluid retention is observed, therefore it is recommended to regularly monitor the body weight of patients. In case of rapid sudden increase in body weight, a patient should be examined and, if necessary, a maintenance therapy (diuretics) and / or temporarily discontinued therapy with the drug. The highest frequency of fluid retention is observed in elderly patients with concomitantcardiovascular diseases. Caution is necessary to prescribe the drug to elderly patients with impaired cardiac function.

    In some cases, severe fluid retention may have a severe course with a fatal outcome. When imatinib was used in a patient with CML in the phase of blast crisis and a complex of symptoms (pleural effusion, chronic cardiac and renal insufficiency), a lethal outcome was noted.

    Patients with heart disease

    Careful monitoring of patients with heart disease, with risk factors for heart failure or with renal insufficiency in the medical history should be ensured. Patients with signs and symptoms that indicate the development of cardiac or renal insufficiency should undergo a screening for their detection and, if necessary, appropriate treatment should be prescribed.

    In patients with hypereosinophilia syndrome with latent infiltration of eosinophils into the myocardium, at the beginning of imatinib therapy, single cases of development of cardiogenic shock / left ventricular failure, which were associated with degranulation of eosinophils, were observed.These undesirable effects stop after the administration of systemic glucocorticosteroids (GCS), as well as taking measures aimed at maintaining blood circulation, and temporary discontinuation of Imatinib-Aktavis. Since cardiac adverse events are rare but occur, before the initiation of imatinib therapy, the benefit / risk ratio in patients with hypereosinophilia and / or HAL syndrome should be carefully evaluated.

    Myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with gene rearrangements of the platelet-derived growth factor receptor may be associated with a high level of eosinophils. Patients with hypereosinophilia and / or HAL syndrome, as well as patients with MDS / MPD associated with a high level of eosinophils should receive advice from a cardiologist with echocardiography and a serum concentration of cardiospecific troponin before starting therapy. If abnormalities are found, at the beginning of therapy should be considered the possibility of preventive use of systemic GCS (1-2 mg / kg) for 1-2 weeks concurrently with the drug.

    Hepatotoxicity

    Metabolism of imatinib is mainly carried out in the liver and only 13% of it is excreted by the kidneys. In patients with impaired hepatic function (light, medium and severe), regular clinical studies of peripheral blood and monitoring of liver function ("hepatic" transaminases, bilirubin, alkaline phosphatase) are recommended when using Imatinib-Aktavis. It should be taken into account that patients with stromal tumors of the gastrointestinal tract may have metastases in the liver, which can be the cause of hepatic insufficiency. When imatinib was taken, there were cases of development of damaging effects on the liver, including hepatic insufficiency and liver necrosis. When combining therapy with imatinib with high doses of chemotherapy, an increase in the number of severe liver reactions was detected. When prescribing the drug in combination with chemotherapy, as well as in the presence of a violation of liver function, clinical and liver function tests should be performed carefully and regularly.

    Hypothyroidism

    Since there are reports of the development of hypothyroidism with imatinib in patients,who underwent thyroidectomy and who received substitution treatment with levothyroxine sodium, it is necessary to regularly determine the concentration of thyroid-stimulating hormone (TSH) in this category of patients.

    Bleeding of the gastrointestinal tract

    In patients with inoperable and / or metastatic malignant GISO, bleeding in the gastrointestinal tract and bleeding from tumor sites were observed in clinical studies (see section "Side effect"). Based on the obtained data, there were no factors predisposing to a high risk of bleeding in patients with malignant GIS (for example, tumor size and location, coagulation disorders). Since the signs of a neoplasm are the presence of a zone of increased vascularization and a predisposition to bleeding, it is necessary to monitor the presence of bleeding and be ready to eliminate them in this group of patients.

    Deviations in the results of laboratory tests

    Regular monitoring of the blood picture during drug therapy is necessary. Treatment with imatinib patients with CML is associated with the occurrence of neutropenia or thrombocytopenia.However, the incidence of cytopenia is likely to be related to the stage of the disease, and these complications were more often observed in patients in the phase of CML acceleration or in the blast crisis phase compared to patients in the chronic phase of CML. In this case, treatment with the drug may be interrupted or the dose may be reduced as recommended in section "Mode of administration and dose."

    In patients taking Imatinib-Aktavis. should regularly monitor liver function (the activity of "liver" transaminases, bilirubin, alkaline phosphatase). In patients with impaired renal function, imatinib concentration is higher compared to patients with normal renal function. Perhaps this is due to an increase in the concentration of acid alpha-glycoprotein in this group of patients that binds to imatinib. Patients with impaired renal function should receive a minimum initial dose. Caution should be taken in patients with severe impairment of kidney function. In the case of poor drug tolerance, the dose should be reduced.

    A marked increase in the activity of "hepatic" transaminases or bilirubin was noted in less,than 3% of patients with CML and usually controlled by a decrease in the dose of the drug or temporary interruption of treatment (the average duration of such episodes was about 1 week).

    Tumor lysis syndrome

    Due to the risk of development of tumor lysis syndrome, Imatinib-Aktavis should be corrected, if necessary, for a clinically pronounced decrease in the total volume of circulating blood and an increased concentration of uric acid in patients.

    Effect on the ability to drive transp. cf. and fur:

    Some of the side effects of Imatinib-Aktavis, such as dizziness, blurred vision or drowsiness, can adversely affect the ability to drive vehicles and perform potentially dangerous activities that require increased attention and speed of psychomotor reactions. In this regard, patients receiving imatinib, there should be increased attention and caution in the management of vehicles and the implementation of potentially hazardous activities.

    Form release / dosage:

    Capsules 100 mg.

    Packaging:

    For 8 or 10 capsules per blister Aklar-PVC / Al.

    For 3, 6, 12 blisters for 8 capsules or 6, 12, 18 blisters for 10 capsules with instructions for use in a cardboard bundle.

    Storage conditions:

    At a temperature of no higher than 25 ° C.

    Keep out of the reach of children!

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-004263
    Date of registration:28.04.2017
    Expiration Date:28.04.2022
    The owner of the registration certificate:Actavis PTS ehf GroupActavis PTS ehf Group Iceland
    Manufacturer: & nbsp
    Representation: & nbspAktavis, Open Company Aktavis, Open Company
    Information update date: & nbsp19.06.2017
    Illustrated instructions
      Instructions
      Up